Free tool
FAERS Monitor: Lotrimin Af
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020889 or its brand name (Lotrimin Af, Clotrimazole). Reports on generic versions are filed under their own applications.
Reports
1,437
Serious
659
46% of reports
Hospitalization
314
Death reported
86
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- vulvovaginal burning sensation242
- drug ineffective180
- vulvovaginal pain79
- condition aggravated75
- vulvovaginal pruritus73
- off label use71
- drug interaction58
- vulvovaginal discomfort47
- constipation46
- abdominal pain43
- vaginal haemorrhage42
- hypersensitivity41
- international normalised ratio increased41
- pain41
- sepsis41
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 11 |
| 2005 | 11 |
| 2006 | 18 |
| 2007 | 5 |
| 2008 | 28 |
| 2009 | 47 |
| 2010 | 31 |
| 2011 | 41 |
| 2012 | 94 |
| 2013 | 56 |
| 2014 | 32 |
| 2015 | 20 |
| 2016 | 50 |
| 2017 | 51 |
| 2018 | 44 |
| 2019 | 57 |
| 2020 | 98 |
| 2021 | 114 |
| 2022 | 140 |
| 2023 | 94 |
| 2024 | 107 |
| 2025 | 136 |
| 2026 | 152 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,722 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| vulvovaginal burning sensationSignal | 242 | 604.2 | 537.1 | 139,421 |
| vulvovaginal painSignal | 79 | 244.0 | 196.6 | 18,573 |
| vulvovaginal pruritusSignal | 73 | 214.0 | 170.9 | 15,050 |
| vulvovaginal discomfortSignal | 47 | 157.3 | 118.6 | 7,070 |
| international normalised ratio increasedSignal | 41 | 21.1 | 15.6 | 764 |
| vaginal haemorrhageSignal | 42 | 14.2 | 10.5 | 502 |
| sepsisSignal | 41 | 5.4 | 4.0 | 143 |
| drug interactionSignal | 58 | 5.4 | 4.2 | 202 |
| condition aggravatedSignal | 75 | 3.6 | 2.9 | 141 |
| hypersensitivitySignal | 41 | 3.2 | 2.4 | 62 |
| constipationSignal | 46 | 3.1 | 2.3 | 64 |
| abdominal painSignal | 43 | 2.7 | 2.0 | 45 |
| drug ineffective | 180 | 2.0 | 1.7 | 95 |
| off label use | 71 | 1.2 | 0.9 | 2 |
| pain | 41 | 1.0 | 0.7 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.